Guideline on the requirements for demonstrating Therapeutic equivalence between orally inhaled products (OIP) for asthma [Regulatives / Guidelines]

posted by qualityassurance – 2025-09-25 09:41 (277 d 06:56 ago) – Posting: # 24447
Views: 1,556

Dear all,

EMA has rcently released Guideline on the requirements for demonstrating Therapeutic equivalence between orally inhaled products (OIP) for asthma and chronic obstructive pulmonary disease (COPD) EMA guideline.

It is stated that This guideline replaces "Guideline on the requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulmonary disease (COPD) in adults and for use in the treatment of asthma in children and adolescents (CPMP/EWP/4151/00 Rev. 1)”

Based on above statement, can we consider this guideline for development of nasal spray for the treatment of seasonal allergic rhinitis?
Can we demonstrate equivalence through in vitro data only (our formulation is not Q1/Q2 similar)?

Looking forwad for expert opinions.

Regards,
QA

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,570 registered users;
278 visitors (0 registered, 278 guests [including 28 identified bots]).
Forum time: 16:38 CEST (Europe/Vienna)

Most scientists today are devoid of ideas, full of fear, intent on
producing some paltry result so that they can add to the flood
of inane papers that now constitutes “scientific progress”
in many areas.    Paul Feyerabend

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5